Cite
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
MLA
Mosenzon, Ofri, et al. “The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.” Diabetes Care, vol. 44, no. 8, Aug. 2021, pp. 1805–15. EBSCOhost, https://doi.org/10.2337/dc21-0076.
APA
Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., Rozenberg, A., Schechter, M., Yanuv, I., Murphy, S. A., Zelniker, T. A., Gause-Nilsson, I. A. M., Langkilde, A. M., Fredriksson, M., Johansson, P. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., & Sabatine, M. S. (2021). The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 44(8), 1805–1815. https://doi.org/10.2337/dc21-0076
Chicago
Mosenzon, Ofri, Stephen D. Wiviott, Hiddo J.L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, et al. 2021. “The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.” Diabetes Care 44 (8): 1805–15. doi:10.2337/dc21-0076.